Big Data for outcomes and clinical research:

major advance or improvement needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login